Wu HX - Search Results

1

Development of antibody-drug conjugates in cancer: Overview and prospects.

Ruan DY, Wu HX, Meng Q, Xu RH. Ruan DY, et al. Among authors: wu hx. Cancer Commun (Lond). 2024 Jan;44(1):3-22. doi: 10.1002/cac2.12517. Epub 2023 Dec 30. Cancer Commun (Lond). 2024. PMID: 38159059 Free PMC article. Review.

2

Appraisal of Prognostic Interaction between Sidedness and Mucinous Histology in Colon Cancer: A Population-Based Study Using Inverse Probability Propensity Score Weighting.

Wang ZX, Yang LP, Wu HX, Yang DD, Ding PR, Xie D, Chen G, Li YH, Wang F, Xu RH. Wang ZX, et al. Among authors: wu hx. J Cancer. 2019 Jan 1;10(2):388-396. doi: 10.7150/jca.28014. eCollection 2019. J Cancer. 2019. PMID: 30719132 Free PMC article.

3

Correlation of Milestone Restricted Mean Survival Time Ratio With Overall Survival Hazard Ratio in Randomized Clinical Trials of Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis.

Wang ZX, Wu HX, Xie L, Wang YN, Yang LP, He MM, Luo HY, Ding PR, Xie D, Chen G, Li YH, Wang F, Xu RH. Wang ZX, et al. Among authors: wu hx. JAMA Netw Open. 2019 May 3;2(5):e193433. doi: 10.1001/jamanetworkopen.2019.3433. JAMA Netw Open. 2019. PMID: 31050784 Free PMC article.

4

A real-world evidence of efficacy of palliative gastrectomy plus chemotherapy in metastatic gastric cancer patients.

Yang LP, Wang ZX, He MM, Wu HX, Yuan SQ, Wang W, Jin Y, Ren C, Wang ZQ, Wang FH, Li YH, Wang F, Xu RH. Yang LP, et al. Among authors: wu hx. Cancer Manag Res. 2019 May 2;11:3993-4003. doi: 10.2147/CMAR.S197052. eCollection 2019. Cancer Manag Res. 2019. PMID: 31118812 Free PMC article.

5

Chemotherapy With or Without Anti-EGFR Agents in Left- and Right-Sided Metastatic Colorectal Cancer: An Updated Meta-Analysis.

Wang ZX, Wu HX, He MM, Wang YN, Luo HY, Ding PR, Xie D, Chen G, Li YH, Wang F, Xu RH. Wang ZX, et al. Among authors: wu hx. J Natl Compr Canc Netw. 2019 Jul 1;17(7):805-811. doi: 10.6004/jnccn.2018.7279. J Natl Compr Canc Netw. 2019. PMID: 31319395

6

Designing gene panels for tumor mutational burden estimation: the need to shift from 'correlation' to 'accuracy'.

Wu HX, Wang ZX, Zhao Q, Wang F, Xu RH. Wu HX, et al. J Immunother Cancer. 2019 Aug 6;7(1):206. doi: 10.1186/s40425-019-0681-2. J Immunother Cancer. 2019. PMID: 31387639 Free PMC article.

7

Alteration in TET1 as potential biomarker for immune checkpoint blockade in multiple cancers.

Wu HX, Chen YX, Wang ZX, Zhao Q, He MM, Wang YN, Wang F, Xu RH. Wu HX, et al. J Immunother Cancer. 2019 Oct 17;7(1):264. doi: 10.1186/s40425-019-0737-3. J Immunother Cancer. 2019. PMID: 31623662 Free PMC article.

8

Exploration of modified progression-free survival as a novel surrogate endpoint for overall survival in immuno-oncology trials.

Wang ZX, Wu HX, Xie L, Lin WH, Liang F, Li J, Yang ZM, Xu RH. Wang ZX, et al. Among authors: wu hx. J Immunother Cancer. 2021 Apr;9(4):e002114. doi: 10.1136/jitc-2020-002114. J Immunother Cancer. 2021. PMID: 33795385 Free PMC article.

9

Postoperative circulating tumor DNA as markers of recurrence risk in stages II to III colorectal cancer.

Chen G, Peng J, Xiao Q, Wu HX, Wu X, Wang F, Li L, Ding P, Zhao Q, Li Y, Wang D, Shao Y, Bao H, Pan Z, Ding KF, Cai S, Wang F, Xu RH. Chen G, et al. Among authors: wu hx, wu x. J Hematol Oncol. 2021 May 17;14(1):80. doi: 10.1186/s13045-021-01089-z. J Hematol Oncol. 2021. PMID: 34001194 Free PMC article.

10

Advancing to the era of cancer immunotherapy.

Wang Y, Wang M, Wu HX, Xu RH. Wang Y, et al. Among authors: wu hx. Cancer Commun (Lond). 2021 Sep;41(9):803-829. doi: 10.1002/cac2.12178. Epub 2021 Jun 24. Cancer Commun (Lond). 2021. PMID: 34165252 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

427 results

Search Page